EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Bedaquiline resistance in patients with Xpert MTB/RIF Ultra-tested rifampicin-resistant tuberculosis in the Western Cape, South Africa: a prospective study

Janré Steyn, Jennifer Williams, Fahd Naufal, Jason Limberis, Melanie Grobbelaar, Nabila Ismail, Yonas Ghebrekristos, Christoffel J Opperman, Alina Nalyvayko, Sarishna Singh, Rebecca E Colman, Timothy C Rodwell und 3 weitere

The Lancet Microbe · 2026

DOI: 10.1016/j.lanmic.2025.101293 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Lancet Microbe, 2026. Verfasst von Janré Steyn und 14 weiteren Autor:innen. Beteiligte Einrichtung: SAMRC Centre for Tuberculosis Research, DSI-NRF Centre of Excellence for Biomedical Tuberculosis Research, Division of Molecular Biology and Human Ge…. Hauptthemen laut MEDLINE: Rifampin, Mycobacterium tuberculosis, Tuberculosis, Multidrug-Resistant, Diarylquinolines. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Bedaquiline-containing regimens have been widely used to treat patients with drug-resistant tuberculosis in South Africa since 2019. We aimed to estimate the prevalence of bedaquiline resistance among patients in the Western Cape with rifampicin-resistant tuberculosis tested by Xpert MTB/RIF Ultra (Xpert). METHODS: This prospective study analysed consecutive Mycobacterium tuberculosis diagnostic isolates collected from patients with Xpert-tested rifampicin-resistant tuberculosis in the Western Cape, South Africa, between March 30, 2023, and Jan 3, 2024. We used the Deeplex Myc-TB assay within routine clinical workflows to test genotypic resistance to bedaquiline and other antituberculosis drugs; mmpR5 variants were classified according to Deeplex version 3.0.1 extended catalogue. Phenotypic drug susceptibility information was derived from the National Health Laboratory System and Stellenbosch University for isolates with a Deeplex-identified mmpR5 variant. We estimated the prevalence of bedaquiline resistance and the diagnostic accuracy of Deeplex for bedaquiline susceptibility using a composite genotypic-phenotypic reference standard. FINDINGS: Of 701 sputum sediments, 131 (19%) were culture-negative. Of the 570 isolates accumulated during the study period, Deeplex was not performed for 139 during intervals trialling workflow optimisation procedures. Of 431 isolates, we successfully sequenced 401 (93%), of which 15 (4%) were found to be rifampicin-susceptible; 364 (91%) analysed isolates were baseline and 37 (9%) were longitudinal (median estimated time since previous diagnosis of 5·4 months [IQR 3·7-8·0]). Bedaquiline resistance was detected in 45 (12% [95% CI 9-16]) of 364 baseline and 15 (41% [25-58]) of 37 longitudinal isolates. Deeplex-tested resistance-associated and uncharacterised mmpR5 variants had a similar likelihood of being phenotypic drug susceptibility testing-resistant (37 [97%] of 38 and 16 [94%] of 17, respectively; p=0·53). Combining both types of variants, Deeplex had a sensitivity of 93% (95% CI 83-98) and specificity of 99% (97-100). INTERPRETATION: In a prospective, representative sample of patients with Xpert-tested rifampicin-resistant tuberculosis, we found an elevated prevalence of bedaquiline resistance, particularly in patients with recent tuberculosis treatment. Efficient and accurate surveillance for bedaquiline resistance should be a high programmatic priority. FUNDING: The National Institute of Allergy and Infectious Diseases (at the National Institutes of Health) and Unitaid.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RifampinMycobacterium tuberculosisTuberculosis, Multidrug-ResistantDiarylquinolinesAntitubercular AgentsHumansSouth AfricaProspective StudiesMicrobial Sensitivity TestsGenotypePrevalenceDrug Resistance, BacterialFemaleMale

Substanzen

RifampinbedaquilineDiarylquinolinesAntitubercular Agents

Autor:innen und Institutionen

  • SAMRC Centre for Tuberculosis Research, DSI-NRF Centre of Excellence for Biomedical Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch Universi…
  • Division of Pulmonary and Critical Care Medicine, Zuckerberg San Francisco General Hospital and Trauma Centre, University of California San Francisco, San Francisco, CA, USA.
  • Division of Pulmonary, Critical Care, Sleep Medicine, and Physiology, University of California San Diego, San Diego, CA, USA.
  • Division of Pulmonary and Critical Care Medicine, Zuckerberg San Francisco General Hospital and Trauma Centre, University of California San Francisco, San Francisco, CA, USA. Electronic address: john.metcalfe@ucsf.edu.

Förderung

  • NIAID NIH HHS
  • National Institute of Allergy and Infectious Diseases

Zitieren

APA

Steyn, J., Williams, J., Naufal, F., Limberis, J., Grobbelaar, M., Ismail, N., Ghebrekristos, Y., Opperman, C. J., Nalyvayko, A., Singh, S., Colman, R. E., Rodwell, T. C., Theron, G., Warren, R. M., & Metcalfe, J. Z. (2026). Bedaquiline resistance in patients with Xpert MTB/RIF Ultra-tested rifampicin-resistant tuberculosis in the Western Cape, South Africa: a prospective study. The Lancet Microbe. https://doi.org/10.1016/j.lanmic.2025.101293

Vancouver

Steyn J, Williams J, Naufal F, Limberis J, Grobbelaar M, Ismail N, et al. Bedaquiline resistance in patients with Xpert MTB/RIF Ultra-tested rifampicin-resistant tuberculosis in the Western Cape, South Africa: a prospective study. The Lancet Microbe. 2026. doi:10.1016/j.lanmic.2025.101293

BibTeX
@article{Steyn2026,
  author = {Steyn, Janré and Williams, Jennifer and Naufal, Fahd and Limberis, Jason and Grobbelaar, Melanie and Ismail, Nabila and Ghebrekristos, Yonas and Opperman, Christoffel J and Nalyvayko, Alina and Singh, Sarishna and Colman, Rebecca E and Rodwell, Timothy C and Theron, Grant and Warren, Robin M and Metcalfe, John Z},
  title = {Bedaquiline resistance in patients with Xpert MTB/RIF Ultra-tested rifampicin-resistant tuberculosis in the Western Cape, South Africa: a prospective study},
  journal = {The Lancet Microbe},
  year = {2026},
  doi = {10.1016/j.lanmic.2025.101293}
}
Kostenlos starten →